Pemafibrate and coronary plaque characteristics
- Conditions
- Acute coronary syndrome (ACS)Acute coronary syndome, Pemafibrate, lipid plaque
- Registration Number
- JPRN-jRCTs051190100
- Lead Sponsor
- ogi Kazutaka
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
1. ACS (STEMI or NSTEMI/Unstable angina)
2. Presence of coronary lipid plaque (fibrous cap thickness < or = 0.2 mm, and lipid angle > or = 90 degree) more than 5 mm from the target lesion for PCI
3. TG>150mg/dl
4. Age>20yo
5. Written informed consent obtained
1. SVG or in-stent restenosis lesion
2. Previous history of PCI to the target lesion
3. Vessel with diffuse coronary artery stenosis which is scheduled for PCI
4. Insulin user
5. Cardiogenic shock
6. Allergy to the study drug (Pemafibrate)
7. Severe lever injury, liver cirrhosis, or bile duct obstruction
8. Moderate to severe renal dysfunction(SCr > or = 1.5 mg/dl)
9. Presence of bile stone
10. pregnant or lactating woman
11. Use of Cyclosporine or Rifampicin
12. Use of other fibrates, omega-3 polyunsaturated fatty acids, or nicotinic acid derivatives
13. Those who are considered as unsuitable candidate by investigators
14. Those who are psyhosis, or are difficault to participate because of psychiatric symptoms
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method